Literature DB >> 8454612

Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase.

D C Zeldin1, J Kobayashi, J R Falck, B S Winder, B D Hammock, J R Snapper, J H Capdevila.   

Abstract

The hydration of cis-epoxyeicosatrienoic acids to the corresponding vic-dihydroxyeicosatrienoic acids by cytosolic epoxide hydrolase demonstrates moderate regioselectivity with rates of hydration highest for the 14,15-epoxide and lower for the 11,12- and 8,9-epoxide (4.5, 1.6, and 1.5 mumol of product/mg of protein/min, respectively). Incubations of the 8,9- and 14,15-epoxides with cytosolic epoxide hydrolase show stereoselective formation of diols (7:3 and 4:1 ratio of antipodes, respectively) and concomitant chiral enrichment of the remaining unmetabolized substrate. In contrast, hydration of the 11,12-epoxide is nonenantioselective. The Km value of the enzyme for the 14(R),15(S)-epoxide is 3 microM. Incubations of the enantiomerically pure 8,9- and 14,15-epoxides with lung or liver cytosol, followed by chiral analysis of the resulting diols demonstrate selective cleavage of the oxirane ring at C9 and C15, respectively. On the other hand, cleavage of the 11,12- oxirane ring was less selective. The stereochemical preference of the cytosolic epoxide hydrolase, together with the known chiral composition of the endogenous arachidonate epoxide pools, suggests a functional role for this enzyme in the metabolism of these important compounds.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8454612

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  73 in total

1.  11,12,20-Trihydroxy-eicosa-8(Z)-enoic acid: a selective inhibitor of 11,12-EET-induced relaxations of bovine coronary and rat mesenteric arteries.

Authors:  Ishfaq A Bukhari; Abdul Jabbar Shah; Kathryn M Gauthier; Katherine A Walsh; Sreenivasulu Reddy Koduru; John D Imig; John R Falck; William B Campbell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-03       Impact factor: 4.733

2.  Symmetric adamantyl-diureas as soluble epoxide hydrolase inhibitors.

Authors:  Vladimir Burmistrov; Christophe Morisseau; Kin Sing Stephen Lee; Diyala S Shihadih; Todd R Harris; Gennady M Butov; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2014-03-20       Impact factor: 2.823

Review 3.  EET signaling in cancer.

Authors:  Dipak Panigrahy; Emily R Greene; Ambra Pozzi; Dao Wen Wang; Darryl C Zeldin
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

4.  Human soluble epoxide hydrolase: structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids.

Authors:  German A Gomez; Christophe Morisseau; Bruce D Hammock; David W Christianson
Journal:  Protein Sci       Date:  2005-12-01       Impact factor: 6.725

5.  Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies.

Authors:  Paul D Jones; Nicola M Wolf; Christophe Morisseau; Paul Whetstone; Bertold Hock; Bruce D Hammock
Journal:  Anal Biochem       Date:  2005-08-01       Impact factor: 3.365

6.  Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles.

Authors:  Kathryn M Gauthier; Lauren Olson; Adam Harder; Marilyn Isbell; John D Imig; David D Gutterman; J R Falck; William B Campbell
Journal:  Am J Physiol Renal Physiol       Date:  2011-07-13

7.  Chiral lipidomics of monoepoxy and monohydroxy metabolites derived from long-chain polyunsaturated fatty acids.

Authors:  Maximilian Blum; Inci Dogan; Mirjam Karber; Michael Rothe; Wolf-Hagen Schunck
Journal:  J Lipid Res       Date:  2018-11-08       Impact factor: 5.922

Review 8.  Metabolic/inflammatory/vascular comorbidity in psychiatric disorders; soluble epoxide hydrolase (sEH) as a possible new target.

Authors:  W Swardfager; M Hennebelle; D Yu; B D Hammock; A J Levitt; K Hashimoto; A Y Taha
Journal:  Neurosci Biobehav Rev       Date:  2018-02-02       Impact factor: 8.989

9.  Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation.

Authors:  Kimberly L Fife; Yingmei Liu; Kara R Schmelzer; Hsing-Ju Tsai; In-Hae Kim; Christophe Morisseau; Bruce D Hammock; Deanna L Kroetz
Journal:  J Pharmacol Exp Ther       Date:  2008-09-24       Impact factor: 4.030

10.  Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase.

Authors:  Alan R Parrish; Gang Chen; Robert C Burghardt; Takaho Watanabe; Christophe Morisseau; Bruce D Hammock
Journal:  Cell Biol Toxicol       Date:  2008-04-03       Impact factor: 6.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.